Anthropic's Long-Term Benefit Trust appointed Novartis CEO Vas Narasimhan to the company's board of directors, the first executive from pharma to join the AI startup's governing body. With the addition, Trust-appointed directors now constitute a majority of the full board, strengthening the mechanism meant to keep Anthropic accountable to its public-benefit mission. President Daniela Amodei cited Narasimhan's record of bringing "powerful new technologies to people safely and at scale" in one of the world's most regulated industries as the rationale. The appointment comes as Anthropic considers a public listing as early as October 2026 and is fielding investor interest at elevated valuations.